drugset / Trial / NCT01314885

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

NCT01314885

Phase 1 Completed 39 enrolled Pfizer
RandomizedCrossoverDouble-blind

Summary

A single dose study with the inhaled anti-inflammatory agent PF-03715455 to establish if it has anti-inflammatory activity following a challenge with LPS. Inhaled LPS invokes an acute inflammatory response in the lung which can be seen in induced sputum. PH-0797804 is an internal control for the study.

Timeline

Start
2011-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03715455 Small molecule 20 mg Inhaled
Subject PH-797804 Small molecule 30 mg Oral